JP2015524845A - 低ａａｇ患者の癌の治療に使用するためのａｒｒｙ−５２０ - Google Patents

低ａａｇ患者の癌の治療に使用するためのａｒｒｙ−５２０ Download PDF

Info

Publication number
JP2015524845A
JP2015524845A JP2015527550A JP2015527550A JP2015524845A JP 2015524845 A JP2015524845 A JP 2015524845A JP 2015527550 A JP2015527550 A JP 2015527550A JP 2015527550 A JP2015527550 A JP 2015527550A JP 2015524845 A JP2015524845 A JP 2015524845A
Authority
JP
Japan
Prior art keywords
patient
aag
arry
cancer
low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015527550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524845A5 (enExample
Inventor
カリン ブラウン，
カリン ブラウン，
ロナルド ビー． フランクリン，
ロナルド ビー． フランクリン，
ゲイリー ピー． ヒンゴラーニ，
ゲイリー ピー． ヒンゴラーニ，
ケビン エス． リットウィラー，
ケビン エス． リットウィラー，
ブライアン ジェイ． タンクィスト，
ブライアン ジェイ． タンクィスト，
ダンカン エイチ． ウォーカー，
ダンカン エイチ． ウォーカー，
Original Assignee
アレイ バイオファーマ、インコーポレイテッド
アレイ バイオファーマ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50101460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015524845(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アレイ バイオファーマ、インコーポレイテッド, アレイ バイオファーマ、インコーポレイテッド filed Critical アレイ バイオファーマ、インコーポレイテッド
Publication of JP2015524845A publication Critical patent/JP2015524845A/ja
Publication of JP2015524845A5 publication Critical patent/JP2015524845A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2015527550A 2012-08-13 2013-08-13 低ａａｇ患者の癌の治療に使用するためのａｒｒｙ−５２０ Pending JP2015524845A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261682682P 2012-08-13 2012-08-13
US61/682,682 2012-08-13
US201261734149P 2012-12-06 2012-12-06
US61/734,149 2012-12-06
US201361829779P 2013-05-31 2013-05-31
US61/829,779 2013-05-31
PCT/US2013/054807 WO2014028543A1 (en) 2012-08-13 2013-08-13 Arry-520 for use in treating cancer in a patient with low aag

Publications (2)

Publication Number Publication Date
JP2015524845A true JP2015524845A (ja) 2015-08-27
JP2015524845A5 JP2015524845A5 (enExample) 2016-09-29

Family

ID=50101460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015527550A Pending JP2015524845A (ja) 2012-08-13 2013-08-13 低ａａｇ患者の癌の治療に使用するためのａｒｒｙ−５２０

Country Status (19)

Country Link
US (1) US20150231117A1 (enExample)
EP (1) EP2882436A1 (enExample)
JP (1) JP2015524845A (enExample)
KR (1) KR20150042280A (enExample)
CN (1) CN104869995A (enExample)
AU (1) AU2013302762A1 (enExample)
BR (1) BR112015003192A2 (enExample)
CA (1) CA2881937A1 (enExample)
CL (1) CL2015000348A1 (enExample)
CR (1) CR20150134A (enExample)
HK (1) HK1206275A1 (enExample)
IL (1) IL237227A0 (enExample)
IN (1) IN2015KN00676A (enExample)
MX (1) MX2015002018A (enExample)
NZ (1) NZ631362A (enExample)
PH (1) PH12015500306A1 (enExample)
RU (1) RU2617392C2 (enExample)
SG (1) SG11201501106TA (enExample)
WO (1) WO2014028543A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505924A (ja) * 2008-10-16 2012-03-08 アレイ バイオファーマ、インコーポレイテッド 治療におけるアポトーシスを増加させるための有糸分裂の阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
DE602005008953D1 (de) * 2004-05-21 2008-09-25 Novartis Vaccines & Diagnostic Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
US7449486B2 (en) 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
US9561214B2 (en) 2008-10-16 2017-02-07 Array Biopharma Inc. Method of treatment using inhibitors of mitosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505924A (ja) * 2008-10-16 2012-03-08 アレイ バイオファーマ、インコーポレイテッド 治療におけるアポトーシスを増加させるための有糸分裂の阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, vol. 9, JPN6017019615, 2003, pages 1077 - 1082, ISSN: 0003705599 *
日本臨床検査自動化学会会誌, vol. 15, no. 3, JPN6017019617, 1990, pages 197 - 202, ISSN: 0003568215 *

Also Published As

Publication number Publication date
CA2881937A1 (en) 2014-02-20
US20150231117A1 (en) 2015-08-20
MX2015002018A (es) 2015-10-09
HK1206275A1 (en) 2016-01-08
EP2882436A1 (en) 2015-06-17
RU2015108740A (ru) 2016-09-27
CR20150134A (es) 2015-05-06
IL237227A0 (en) 2015-04-30
BR112015003192A2 (pt) 2017-08-08
RU2617392C2 (ru) 2017-04-24
SG11201501106TA (en) 2015-06-29
CN104869995A (zh) 2015-08-26
WO2014028543A1 (en) 2014-02-20
CL2015000348A1 (es) 2015-04-24
NZ631362A (en) 2016-09-30
IN2015KN00676A (enExample) 2015-07-17
AU2013302762A1 (en) 2014-10-02
KR20150042280A (ko) 2015-04-20
PH12015500306A1 (en) 2015-04-20

Similar Documents

Publication Publication Date Title
US12320799B2 (en) Methods of measuring signaling pathway activity for selection of therapeutic agents
US10976307B2 (en) Whole cell assays and methods
Laroche-Clary et al. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
AU2015360260B2 (en) Methods of measuring ErbB signaling pathway activity to diagnose and treat cancer patients
Chu et al. Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex
US20130012407A1 (en) Methods for predicting response of triple-negative breast cancer to therapy
US20240350481A1 (en) Use of n-myristoyl transferase (nmt) inhibitors in the treatment of cancer, autoimmune disorders, and inflammatory disorders
JP2018513850A (ja) がんの処置用のホスホイノシチド３キナーゼ阻害化合物とｃｄｋ４／６阻害剤化合物との組み合わせ
US20090239850A1 (en) Kinase protein binding inhibitors
JP2018523119A (ja) Ｔａｓｅｌｉｓｉｂを用いた治療方法
JP2011522212A (ja) 癌の分類および使用法
Hebert et al. Esomeprazole enhances the effect of ionizing radiation to improve tumor control
US20180021295A1 (en) Methods and materials for assessing chemotherapy responsiveness and treating cancer
Kim et al. Serum BAFF predicts prognosis better than APRIL in diffuse large B‐cell lymphoma patients treated with rituximab plus CHOP chemotherapy
Torres et al. Immunoglobulin E‐mediated hypersensitivity to amoxicillin: in vivo and in vitro comparative studies between an injectable therapeutic compound and a new commercial compound
CN121985960A (zh) 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者
RU2617392C2 (ru) Применение arry-520 для лечения рака у пациентов с низким уровнем акг
KR20260008112A (ko) 파르네실트랜스퍼라제 억제제 및 pi3k 억제제를 사용한 편평 세포 암종의 치료 방법
Cui et al. Cytoplasmic myosin-exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability
US20160025730A1 (en) Methods of selecting combination therapy for colorectal cancer patients
Salas et al. Hypersensitivity reactions to fluoroquinolones
US20190004070A9 (en) Dual anti-platelet medication/aspirin response and reactivity test using synthetic collagen
Hmedat Exploration of new combinatorial therapy candidates for tongue squamous cell carcinomas
Li Indentification of Drug Combinations Exhibiting Synergistic Lethality in Pediatric High-Grade Glioma Pdox Cell Lines
HK40050635A (en) Methods of measuring signaling pathway activity for selection of therapeutic agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170531

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171220